Keywords
Last Name
Institution

Lewis R. Silverman

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756
Fax212-348-9233
    Other Positions
    TitleASSISTANT PROFESSOR
    InstitutionMount Sinai
    DepartmentOncological Sciences


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Navada SC, Steinmann J, Lübbert M, Silverman LR. Clinical development of demethylating agents in hematology. J Clin Invest. 2014 Jan 2; 124(1):40-6.
      View in: PubMed
    2. Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 2013 Sep; 98(9):1421-3.
      View in: PubMed
    3. Ohnuma T, Lehrer D, Ren C, Cho SY, Maniar M, Silverman L, Sung M, Gretz HF, Benisovich V, Navada S, Akahoho E, Wilck E, Taft DR, Roboz J, Wilhelm F, Holland JF. Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3):323-38.
      View in: PubMed
    4. Schmiegelow K, Levinsen MF, Attarbaschi A, Baruchel A, Devidas M, Escherich G, Gibson B, Heydrich C, Horibe K, Ishida Y, Liang DC, Locatelli F, Michel G, Pieters R, Piette C, Pui CH, Raimondi S, Silverman L, Stanulla M, Stark B, Winick N, Valsecchi MG. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013 Jul 1; 31(19):2469-76.
      View in: PubMed
    5. Gore SD, Fenaux P, Santini V, Bennett JM, Silverman LR, Seymour JF, Hellström-Lindberg E, Swern AS, Beach CL, List AF. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 Jul; 98(7):1067-72.
      View in: PubMed
    6. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012 Sep 6; 120(10):2076-86.
      View in: PubMed
    7. Furlong W, Rae C, Feeny D, Gelber RD, Laverdiere C, Michon B, Silverman L, Sallan S, Barr R. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24.
      View in: PubMed
    8. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
      View in: PubMed
    9. Navada SC, Silverman LR. Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions. Curr Hematol Malig Rep. 2011 Mar; 6(1):5-12.
      View in: PubMed
    10. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer. 2011 Jun 15; 117(12):2697-702.
      View in: PubMed
    11. Jatiani SS, Baker SJ, Silverman LR, Reddy EP. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer. 2010 Oct; 1(10):979-93.
      View in: PubMed
    12. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Goekbuget N, Schrappe M, Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15; 117(2):238-49.
      View in: PubMed
    13. Najfeld V, Tripodi J, Scalise A, Silverman LR, Silver RT, Fruchtman S, Hoffman R. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. Br J Haematol. 2010 Nov; 151(3):288-91.
      View in: PubMed
    14. Cho SY, Ohnuma T, Silverman LR, Holland JF, Roboz J. Discontinuous drug binding to proteins: binding of an antineoplastic benzyl styryl sulfone to albumin and enzymes in vitro and in phase I clinical trials. Drug Metab Dispos. 2010 Sep; 38(9):1480-5.
      View in: PubMed
    15. Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL. Effects of azacitidine compared with conventional care regimens in elderly (= 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010 Dec; 76(3):218-27.
      View in: PubMed
    16. Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LR, List A, Gore SD, Seymour JF, Backstrom J, Beach CL. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010 Aug; 85(2):130-8.
      View in: PubMed
    17. Maziasz T, Kadambi VJ, Silverman L, Fedyk E, Alden CL. Predictive toxicology approaches for small molecule oncology drugs. Toxicol Pathol. 2010 Jan; 38(1):148-64.
      View in: PubMed
    18. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 1; 28(4):562-9.
      View in: PubMed
    19. Silverman LR. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk Res. 2009 Dec; 33 Suppl 2:S18-21.
      View in: PubMed
    20. Alencar C, Abramowtiz M, Parekh S, Braunshweig I, Jacobson M, Silverman L, Verma A. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol. 2009 Oct; 84(10):688-9.
      View in: PubMed
    21. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64.
      View in: PubMed
    22. Silverman LR. Clinical roundtable monograph. Overall survival and maintenance of MDS patients. Clin Adv Hematol Oncol. 2009 Jul; 7(7):S3-5.
      View in: PubMed
    23. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24; 114(13):2764-73.
      View in: PubMed
    24. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar; 10(3):223-32.
      View in: PubMed
    25. Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, de Lima M, Gore SD, Potts RG, Silverman LR, Jones RB, McCarthy PL, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009 Feb; 15(2):137-72.
      View in: PubMed
    26. Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C, Stone RM, Bloomfield CD, Larson RA. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 1; 115(1):84-93.
      View in: PubMed
    27. Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, McKenzie D, Beach CL. The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update. Ecancermedicalscience. 2008; 2:118.
      View in: PubMed
    28. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, Li W, McKenna K, Liu XS, Feng B, Neuberg D, Silverman L, DeAngelo DJ, Kutok JL, Rothstein R, DePinho RA, Chin L, Lee C, Look AT. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007 Dec 24; 204(13):3059-66.
      View in: PubMed
    29. Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Hovi L, LeBlanc T, Szczepanski T, Ferster A, Janka G, Rubnitz J, Silverman L, Stary J, Campbell M, Li CK, Mann G, Suppiah R, Biondi A, Vora A, Valsecchi MG. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007 Jul 21; 370(9583):240-50.
      View in: PubMed
    30. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20; 24(24):3895-903.
      View in: PubMed
    31. Silverman LR, Mufti GJ. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nat Clin Pract Oncol. 2005 Dec; 2 Suppl 1:S12-23.
      View in: PubMed
    32. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005 May; 45(5):597-602.
      View in: PubMed
    33. Silverman LR. DNA methyltransferase inhibitors in myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec; 17(4):585-94.
      View in: PubMed
    34. Silverman LR. The role of methyltransferase inhibitors in the management of the myelodysplastic syndromes. Cancer Control. 2004 Nov-Dec; 11(6 Suppl):11-5.
      View in: PubMed
    35. O'Farrell AM, Yuen HA, Smolich B, Hannah AL, Louie SG, Hong W, Stopeck AT, Silverman LR, Lancet JE, Karp JE, Albitar M, Cherrington JM, Giles FJ. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul; 28(7):679-89.
      View in: PubMed
    36. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr 15; 97(8):1920-8.
      View in: PubMed
    37. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL, Cherrington JM, O'Farrell AM, Yuen HA, Louie SG, Hong W, Cortes JE, Verstovsek S, Albitar M, O'Brien SM, Kantarjian HM, Karp JE. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 1; 102(3):795-801.
      View in: PubMed
    38. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, Fehniger TA, Silverman LR, Crawford J, Bloomfield CD, Larson RA, Schiffer CA, Caligiuri MA. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9.
      View in: PubMed
    39. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40.
      View in: PubMed
    40. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, Powell BL, DeCastro C, Ellerton J, Larson RA, Schiffer CA, Holland JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15; 20(10):2441-52.
      View in: PubMed
    41. Morris MM, Schmidt-Ullrich RK, DiNardo L, Manning MA, Silverman L, Clay L, Johnson CR, Amir C. Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):918-28.
      View in: PubMed
    42. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest. 2002; 20(4):452-7.
      View in: PubMed
    43. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist. 2001; 6 Suppl 5:8-14.
      View in: PubMed
    44. Gifford DR, Silverman LR. Treatment of atrial fibrillation with warfarin in Rhode Island. Med Health R I. 2000 May; 83(5):156-7.
      View in: PubMed
    45. Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000 Apr 6; 342(14):998-1006.
      View in: PubMed
    46. Zinzar S, Silverman LR, Richardson EB, Bekesi G, Holland JF. Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90. Leuk Res. 1998 Aug; 22(8):677-85.
      View in: PubMed
    47. Elghetany MT, Peterson B, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Double esterase staining and other neutrophilic granule abnormalities in 237 patients with the myelodysplastic syndrome studied by the cancer and leukemia group B. Acta Haematol. 1998; 100(1):13-6.
      View in: PubMed
    48. Elghetany MT, Peterson B, MacCallum J, Nelson DA, Varney JF, Sullivan AK, Silverman LR, Schiffer CA, Davey FR, Bloomfield CD. Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res. 1997 Sep; 21(9):801-6.
      View in: PubMed
    49. Schlesinger M, Silverman LR, Jiang JD, Yagi MJ, Holland JF, Bekesi JG. Analysis of myeloid and lymphoid markers on the surface and in the cytoplasm of mononuclear bone marrow cells in patients with myelodysplastic syndrome. J Clin Lab Immunol. 1996; 48(4):149-66.
      View in: PubMed
    50. Benisovich VI, Silverman L, Slifkin R, Stone N, Cohen E. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Cancer. 1996 Jan 1; 77(1):160-3.
      View in: PubMed
    51. Najfeld V, Hauschildt B, Scalise A, Gattani A, Patel R, Ambinder EP, Silverman LR. Jumping translocations in leukemia. Leukemia. 1995 Apr; 9(4):634-9.
      View in: PubMed
    52. Silverman LR, Deligdisch L, Mandeli J, Greenspan EM. Chemotherapy for angiosarcoma of the breast: case report of 30-year survival and analysis of the literature. Cancer Invest. 1994; 12(2):145-55.
      View in: PubMed
    53. Silverman L, Sudol M, Resh MD. Members of the src family of nonreceptor tyrosine kinases share a common mechanism for membrane binding. Cell Growth Differ. 1993 Jun; 4(6):475-82.
      View in: PubMed
    54. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, Demakos EP, Cornell CJ, Carey RW, Schiffer C, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993 May; 7 Suppl 1:21-9.
      View in: PubMed
    55. Theodossiou C, Scalise A, Silverman L, Najfeld V. Chromosome 21 rearrangement in acute biphenotypic leukemia. Cancer Genet Cytogenet. 1992 Nov; 64(1):56-9.
      View in: PubMed
    56. Theodossiou C, Scalise A, Troy K, Silverman L, Perdahl-Wallace E, Najfeld V. del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype. Cancer Genet Cytogenet. 1992 Oct 15; 63(2):89-94.
      View in: PubMed
    57. Silverman L, Sigal CT, Resh MD. Binding of pp60v-src to membranes: evidence for multiple membrane interactions. Biochem Cell Biol. 1992 Oct-Nov; 70(10-11):1187-92.
      View in: PubMed
    58. Silverman L, Resh MD. Lysine residues form an integral component of a novel NH2-terminal membrane targeting motif for myristylated pp60v-src. J Cell Biol. 1992 Oct; 119(2):415-25.
      View in: PubMed
    59. Crown J, Lipzstein R, Cohen S, Goldsmith M, Wisch N, Paciucci PA, Silverman L, Weiner M, Jaffrey I, Norton L, et al. Chemotherapy of metastatic Merkel cell cancer. Cancer Invest. 1991; 9(2):129-32.
      View in: PubMed
    60. Kane MJ, Silverman LR, Rand JH, Paciucci PA, Holland JF. Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature. Am J Med. 1988 Dec; 85(6):861-3.
      View in: PubMed
    61. Silverman L, Lee RC, Drinker CK, Rackemann FM. A NEW METHOD FOR STUDYING BREATHING, WITH OBSERVATIONS UPON NORMAL AND ABNORMAL SUBJECTS. J Clin Invest. 1944 Nov; 23(6):907-13.
      View in: PubMed
    Silverman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067